John DeFord - Sep 1, 2023 Form 4 Insider Report for NUVASIVE INC (NUVA)

Role: Director
Signature: /s/ Nathaniel B. Sisitsky, Attorney-in-Fact for John A. DeFord
Stock symbol: NUVA
Transactions as of: Sep 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/5/2023, 04:40 PM
Previous filing: Aug 1, 2023
Next filing: Nov 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	NUVA	Restricted Stock Unit	Disposed to Issuer	$0	-563	-100%	$0.00^*	Sep 1, 2023	Common Stock	563	Direct	F1, F2
transaction	NUVA	Restricted Stock Unit	Disposed to Issuer	$0	-3.23K	-100%	$0.00^*	Sep 1, 2023	Common Stock	3.23K	Direct	F1, F2
transaction	NUVA	Restricted Stock Unit	Disposed to Issuer	$0	-2.58K	-100%	$0.00^*	Sep 1, 2023	Common Stock	2.58K	Direct	F1, F2
transaction	NUVA	Restricted Stock Unit	Disposed to Issuer	$0	-3.1K	-100%	$0.00^*	Sep 1, 2023	Common Stock	3.1K	Direct	F1, F2
transaction	NUVA	Restricted Stock Unit	Disposed to Issuer	$0	-2.7K	-100%	$0.00^*	Sep 1, 2023	Common Stock	2.7K	Direct	F1, F2
transaction	NUVA	Restricted Stock	Disposed to Issuer	$0	-3.79K	-100%	$0.00^*	Sep 1, 2023	Common Stock	3.79K	Direct	F1, F2
transaction	NUVA	Restricted Stock Unit	Disposed to Issuer	$0	-4.82K	-100%	$0.00^*	Sep 1, 2023	Common Stock	4.82K	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John DeFord is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F2	Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

Content

Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.